Infectious Disease Diagnostics Market Outlook 2032
The global infectious disease diagnostics market size was USD 42.3 Billion in 2023 and is likely to reach USD 78.6 Billion by 2032, expanding at a CAGR of 7.1% during 2024–2032. The market growth is attributed to the rising prevalence of infectious diseases and increasing awareness about rapid diagnostics.
Infectious disease diagnostics is a medical field that identifies the cause of infectious diseases, crucial for effective treatment and disease control. Various tests exist, each with strengths and weaknesses, and suitable test depends on the patient's symptoms and suspected illness. Infectious diseases are the leading cause of deaths in North America.
-
In 2018, According to the Centers for Disease Control and Prevention (CDC), approximately 1.7 million infections and 99,000 associated deaths were reported every year in hospitals of North America.
The infectious disease diagnostics market is a thriving sector within the healthcare industry focused on developing and deploying tools to identify the cause of infectious illnesses. This market plays a critical role in combating the spread of diseases and ensuring public health.
The market is experiencing steady growth due to factors such as increasing prevalence of infectious diseases, demand for Point-of-Care testing, technological advancements in AI, machine learning, and molecular diagnostics, increased government initiatives, and public awareness about early diagnosis and the importance of early detection.
Impact of Artificial Intelligence (AI) in Infectious Disease Diagnostics Market
Artificial Intelligence (AI) is revolutionizing the field of infectious disease diagnostics, with the potential to significantly improve accuracy, efficiency, and accessibility of testing. AI-powered algorithms analyze vast amounts of medical data, including images, medical history, and lab results, to identify patterns and anomalies that might be missed by human diagnosticians. This leads to earlier and more accurate diagnoses of infectious diseases.
AI enhance healthcare efficiency by automating repetitive tasks, increasing accessibility in remote settings, and detecting potential outbreaks in real-time. It aids in the development of new diagnostics by analyzing complex biological data, identifying biomarkers, and developing diagnostic tests for infectious diseases.
Infectious Disease Diagnostics Market Dynamics
Major Drivers
Rising prevalence of infectious disease such as HIV, Hepatitis, COVID-19, and typhoid, is increasing the demand of advanced diagnostics, boosting the market. Traditional diagnostic methods often require sending samples to laboratories, leading to delays in diagnosis and treatment. Point-of-Care diagnostics providing rapid results is gaining significant attraction, boosting the market.
Existing Restraints
High cost of diagnostics is limiting the access of these tests in low-and middle-income nations, impeding the market. The high cost of equipment, reagents, and consumables associated with diagnostics is expected to strain healthcare budget. Furthermore, the operational barriers and shortage of skilled workforce is hindering the market. Implementing new diagnostic technologies often requires changes in laboratory workflows and additional training for technicians.
Emerging Opportunities
Development of multiplex testing platforms that simultaneously detect multiple pathogens from a single sample is a promising trend. This improves diagnostic efficiency and provides a comprehensive picture of a patient's infection status. The ongoing threat of emerging infectious diseases such as COVID-19 highlights the need for rapid and reliable POC infectious disease testing. Advancements in POC technologies will be crucial for early detection and outbreak control. For instance,
-
In March 2020, Abbott announced that the fastest molecular point-of-care test for the detection of the novel coronavirus (COVID-19) has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA). The test yields positive results in as little as five minutes and negative results in thirteen.
Scope of the Infectious Disease Diagnostics Market Report
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Infectious Disease Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2023
|
|
Historic Data
|
2017–2022
|
|
Forecast Period
|
2024–2032
|
|
Segmentation
|
Product (Assays Kits & Reagents, Instruments, and Services & Software), Application (Bacterial Infection, Cardiovascular Infection, CNS Infections, Fungal Infection, Gastrointestinal Infection, Sexually Transmitted Disease, Viral Infection, and Other), Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology (INAAT), Immunodiagnostics, DNA Microarray, Clinical Microbiology, DNA sequencing, and Next-generation Sequencing)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Abbott Laboratories; Becton Dickinson and Company; bioMerieus SA; Bio-Rad Laboratories; Danaher Corporation; F Hoffman-La Roche; Hologic Inc.; Luminex Corporation; Qiagen Inc.; and Thermo Fisher Scientific Inc.
|
Infectious Disease Diagnostics Market Segment Insights
Product Segment Analysis
Based on product, the infectious disease diagnostics market is divided into assays kits & reagents, instruments, and services & software. The assays kits & reagents segment dominated the global market in 2023 owing to high demand for it. Assays and reagents are essential components of every diagnostic test, making them consistently in high demand. This demand stems from the rising prevalence of infectious diseases and the increasing number of diagnostic tests conducted globally. Assays and reagents cater to a diverse range of infectious diseases, from well-established illnesses such as HIV and influenza to emerging pathogens such as COVID-19. This versatility ensures their continued relevance in the ever-evolving infectious disease landscape.
Application Segment Analysis
On the basis of application, the global market is segregated into bacterial infection, cardiovascular infection, CNS infections, fungal infection, gastrointestinal infection, sexually transmitted disease, viral infection, and other. The viral segment is anticipated to expand at a considerable CAGR during the forecast period owing to the rising prevalence. Rising incidences of diseases such as influenza, COVID-19, STDs, hepatitis, HIV, is driving the segment. Moreover, the high number of testing volumes and widespread nature of these disease fuel the demand for kits and reagents, thus propelling the segment.
The bacterial infection segment is projected to register a robust growth rate during the assessment years owing to being potentially large segment. Bacterial infections including pneumonia, urinary tract infection, and skin infections, are expected to fuel the segment. The increasing demand for diagnostic tests and frequent healthcare visits is expected to drive the segment significantly.
Technology Segment Analysis
On the basis of technology, the infectious disease diagnostics market is segmented into polymerase chain reaction, isothermal nucleic acid amplification technology (INAAT), immunodiagnostics, DNA microarray, clinical microbiology, DNA sequencing, and next-generation sequencing. The immunodiagnostics segment is expected to expand at a robust pace in the coming years owing to its widespread use. The well-established methods such as, Enzyme-Linked Immunosorbent Assay (ELISA) and rapid diagnostic tests (RDTs) and the high accuracy and speed of immunodiagnostic tests are expected to propel the segment.
The Polymerase Chain Reaction (PCR) segment is estimated to expand at a significant pace during the projection period due to its high accuracy rate. Furthermore, the growing applications and increasing automation technique is expected to boost the segment during the forecast period. Beyond traditional diagnostics, PCR is finding applications in emerging areas such as pharmacogenomics, which studies how a person's genes influence their response to medications. This diversification could fuel the segment.
Regional Analysis
In terms of region, the global infectious disease diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period owing to the rising prevalence of infectious diseases and increasing awareness of the available diagnostic tests among the population. Furthermore, increasing number hospitalization due to the prevalence of infectious disease is expected to propel the regional market. For instance,
-
In 2021, according to information released by CDC, in the US flu season resulted in 9 million illnesses, 4 million medical visits, and 10,000 hospitalizations. In the coming years, market is likely to be driven by the rising burden of diseases.
The market in Asia Pacific is projected to grow at a significant pace in the years to come owing to increasing geriatric population. Rising demand for early disease diagnostics owing to frequent government initiatives is expected to drive the regional market. The growing technical advancements and increasing investments in the healthcare infrastructure is propelling the regional market.
Segments
The infectious disease diagnostics market has been segmented on the basis of
Product
- Assays Kits & Reagents
- Instruments
- Services & Software
Application
- Bacterial Infection
- Cardiovascular Infection
- CNS Infections
- Fungal Infection
- Gastrointestinal Infection
- Sexually Transmitted Disease
- Viral Infection
- Other
Technology
- Polymerase Chain Reaction
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Immunodiagnostics
- DNA Microarray
- Clinical Microbiology
- DNA sequencing
- Next-generation Sequencing
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global infectious disease diagnostics market are Abbott Laboratories; Becton Dickinson and Company; bioMerieus SA; Bio-Rad Laboratories; Danaher Corporation; F Hoffman-La Roche; Hologic Inc.; Luminex Corporation; Qiagen Inc.; and Thermo Fisher Scientific Inc. These companies employ strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. For instance,
- In January 2023, Trinity Biotech announced partnership with Imaware Inc that combined their built-to-partner digital health platform with Trinity Biotech’s advanced reference laboratory facilities to power the Digital Health Industry with at-home and remote testing programs.
- In May 2022, Becton Dickinson and Company announced the launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform in the US.
- In March 2020, Abbott, a global healthcare company, announced the launch of Abbott ID NOW COVID-19 test, which is a molecular point-of-care test used to detect COVID-19 in as little as 5 minutes.
Request For Customization
Enquiry Before Buying
Speak With Analyst
